Announcements
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
- Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
- Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
- Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
- Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
- Ultragenyx lanceert Evkeeza® (evinacumab-concentraatoplossing voor infusie) in Nederland voor de behandeling van homozygote familiaire hypercholesterolemie (HoFH)
- Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
More ▼
Key statistics
As of last trade Ultragenyx Pharmaceutical Inc (R2AR34:SAO) traded at 21.64, -7.44% below its 52-week high of 23.38, set on Mar 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | 25.25 |
Offer | 25.38 |
Previous close | 21.64 |
Average volume | -- |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Jul 23 2024 16:10 BST.
More ▼